Newron Flash Update - Positive “Study 008A” results to trigger a partnering deal

Wednesday, May 1, 2024 @ 12:00 am

Positive results of Study 008A were reported of evenamide in schizophrenia patients who respond inadequately to current antipsychotics. Substantial equity upside to be unlocked upon a partnering deal with a major CNS player and the start of Study 017 in TRS patients.

Key catalysts include:

Release of more detailed “Study 008A” data (coming weeks)
Partnering evenamide with a major CNS player (before starting “Study 017”)
Start pivotal “Study 017” trial of evenamide in TRS (Q4 2024)

Newron Flash Update

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudular mails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask you
October 8, 2024

BD and ten23 Health Partner for aseptic manufacturing

The innovative RFID-based solution for prefilled syringes (PFS) aims to boost efficiency and enhance traceability during the fill-and-finish process and product distribution
October 7, 2024

Alithea Genomics secures loan from Swiss Technology Fund

Alithea Genomics, a leader in large-scale RNA sequencing, received a loan guarantee from Switzerland's Technology Fund, aiding its growth. The fund, part of the Swiss Federal Office for the Environment, supports companies reducing greenhouse gas emissions. Alithea's innovative technologies, such as BRB-seq and DRUG-seq, cut costs, time, and resource use in RNA sequencing, promoting sustainability.
September 24, 2024

Swiss innovators champion industrial biotech: Focus on flexibility, market diversity, and environmental impact

Industrial biotechnology promotes more energy-efficient and sustainable manufacturing processes as well as creating opportunities for reducing pollution, reusing waste and creating new products. It underpins a circular economy and a more sustainable chemicals industry which prioritizes protecting scarce natural resources. New bio-based products and processes have far-reaching and disruptive impact

Mabylon receives over CHF 1.3 million research grants from Innosuisse, Target ALS and ALS Association

Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.
September 24, 2024

ten23 health opens sterile manufacturing facility in Visp

ten23 health, a leading Swiss contract development and manufacturing organization (CDMO), yesterday proudly hosted the Grand Opening of its VIVA2 facility in Visp, Switzerland.
September 24, 2024